BPA
RNAC icon

Beacon Pointe Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Beacon Pointe Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-633
Closed -$21.5K – 1192
2022
Q4 		$21.5K Hold
633
– – ﹤0.01% 1053
2022
Q3 		$31K Buy
+633
New +$34.8K ﹤0.01% 987
2022
Q2 		– Sell
-900
Closed -$33K – 1191
2022
Q1 		$33K Buy
+900
New +$56.3K ﹤0.01% 1177
2021
Q4 		– Sell
-633
Closed -$79K – 993
2021
Q3 		$79K Buy
+633
New +$76.4K ﹤0.01% 883

Other funds holding RNAC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Beacon Pointe Advisors's RNAC Position: Q1 2023 in Review

Beacon Pointe Advisors sold out of Cartesian Therapeutics (RNAC) in Q1 2023, closing a stake of 633 shares — an estimated $21.5K sold.

Beacon Pointe Advisors first reported a position in RNAC in Q3 2021 and held it in 4 quarters. The position peaked at $79K in Q3 2021. 93 funds tracked by Wall St. Rank hold RNAC as of Q1 2023.

  • Beacon Pointe Advisors reported no remaining Cartesian Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Beacon Pointe Advisors sold 633 Cartesian Therapeutics shares in Q1 2023, an estimated $21.5K.
  • Beacon Pointe Advisors first reported a position in Cartesian Therapeutics in Q3 2021 and held it in 4 quarters.
  • Beacon Pointe Advisors's Cartesian Therapeutics position peaked at $79K in Q3 2021.
  • 93 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2023.

Based on Beacon Pointe Advisors's 13F filing for Q1 2023, filed 12 May 2023.